Advantus Capital Management Inc reduced its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 1.4% during the first quarter, Holdings Channel reports. The fund owned 7,241 shares of the medical instruments supplier’s stock after selling 100 shares during the period. Advantus Capital Management Inc’s holdings in C.R. Bard were worth $1,800,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. Creative Planning raised its position in shares of C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock worth $1,068,000 after buying an additional 29 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in shares of C.R. Bard by 3.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 267,451 shares of the medical instruments supplier’s stock worth $60,087,000 after buying an additional 9,134 shares during the last quarter. Fundsmith LLP raised its position in shares of C.R. Bard by 2.1% in the first quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock worth $633,996,000 after buying an additional 52,272 shares during the last quarter. Granite Investment Advisors LLC raised its position in shares of C.R. Bard by 14.3% in the first quarter. Granite Investment Advisors LLC now owns 33,276 shares of the medical instruments supplier’s stock worth $8,270,000 after buying an additional 4,159 shares during the last quarter. Finally, Huntington National Bank raised its position in shares of C.R. Bard by 8.4% in the first quarter. Huntington National Bank now owns 16,411 shares of the medical instruments supplier’s stock worth $4,079,000 after buying an additional 1,278 shares during the last quarter. 88.32% of the stock is currently owned by institutional investors.
Shares of C.R. Bard, Inc. (NYSE BCR) traded down 0.12% on Friday, reaching $313.56. The company had a trading volume of 728,015 shares. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $315.29. The company’s 50-day moving average is $309.48 and its 200 day moving average is $257.26. The firm has a market capitalization of $22.71 billion, a PE ratio of 39.91 and a beta of 0.64.
C.R. Bard (NYSE:BCR) last posted its earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.65 by $0.22. The business had revenue of $938.80 million during the quarter, compared to the consensus estimate of $916.15 million. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. C.R. Bard’s revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the company earned $2.34 EPS. Equities analysts forecast that C.R. Bard, Inc. will post $11.78 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, August 4th. Investors of record on Monday, July 24th will be given a dividend of $0.26 per share. The ex-dividend date is Thursday, July 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio (DPR) is presently 13.21%.
TRADEMARK VIOLATION NOTICE: “[[title]]” was first reported by [[site]] and is the property of of [[site]]. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at [[permalink]].
BCR has been the topic of a number of recent analyst reports. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $276.00 target price on the stock in a research report on Friday, March 3rd. BMO Capital Markets reiterated a “buy” rating and issued a $255.00 price target on shares of C.R. Bard in a report on Tuesday, April 11th. Jefferies Group LLC reiterated a “hold” rating and issued a $237.00 price target on shares of C.R. Bard in a report on Monday, March 27th. Raymond James Financial, Inc. downgraded C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a report on Wednesday, April 26th. Finally, Wells Fargo & Company downgraded C.R. Bard from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 25th. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $265.62.
In related news, VP Frank Lupisella, Jr. sold 3,622 shares of the firm’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the completion of the sale, the vice president now directly owns 10,139 shares of the company’s stock, valued at approximately $3,082,256. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.80% of the stock is owned by company insiders.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.